Ann: Suspension from Official Quotation, page-21

A lot of nicks and cuts along the way but real big bleed (and I will say it again) was the Hygea contract amounting to zip.

$22 million in revenues over a 24 month period was announced and if true that would have been enough for a Nasdaq listing.

Hygea restructuring was BS and some of the more realistic investors here called it.

The Prizma just hasn't resonated within the medical market or with the aging middle class for personal use.

Sad.